Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Develop Peptide-Conjugated Antisense Therapeutics

Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. have announced a new collaboration aimed at discovering and developing peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

The partnership will leverage Orbit’s expertise in peptide discovery to identify and screen cyclic peptides, which will be combined with Secarna’s proprietary ASO molecules. This new approach aims to expand Secarna’s therapeutic capabilities beyond antibodies and sugar molecules.

Konstantin Petropoulos, CBO of Secarna Pharmaceuticals, expressed enthusiasm, stating the collaboration will enhance their development capabilities for targeted antisense therapeutics. Dr. Neil Butt, CEO of Orbit Discovery, echoed this sentiment, highlighting the potential for safer and more effective therapies.

The collaboration is expected to strengthen the creation of targeted antisense therapeutics and could potentially offer new treatment options for a wider range of diseases.